menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advancing Alopecia Areata Treatment: A Look at the FDA Approval of Barcitinib

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Alopecia areata affects more than 300,000 people in the United States each year, causing hair loss to the scalp, eyebrows, and eyelashes. But recent studies have shown that the Janus kinase inhibitor drug baricitinib can help significantly regrow hair for patients. To find out more about what this first-ever FDA approval of a systemic treatment could mean for patients with alopecia areata, Dr. Matthew Keller speaks with Dr. Natasha Mesinkovska, Associate Professor of Dermatology and Vice Chair for Clinical Research of Dermatology at University of California Irvine. 

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Alopecia areata affects more than 300,000 people in the United States each year, causing hair loss to the scalp, eyebrows, and eyelashes. But recent studies have shown that the Janus kinase inhibitor drug baricitinib can help significantly regrow hair for patients. To find out more about what this first-ever FDA approval of a systemic treatment could mean for patients with alopecia areata, Dr. Matthew Keller speaks with Dr. Natasha Mesinkovska, Associate Professor of Dermatology and Vice Chair for Clinical Research of Dermatology at University of California Irvine. 

Facebook Comments

Schedule7 Dec 2022